Caladrix

Caladrix is a forward-thinking biotechnology company dedicated to developing innovative therapeutics for Alzheimer’s disease and related tauopathies. With a strong focus on central nervous system (CNS) disorders, Caladrix is pioneering disease-modifying treatments that aim to restore the brain's natural clearance pathways. The company's mission is driven by the potential of ABCC1, a genetically validated efflux transporter, to export neurotoxic substrates such as amyloid-beta and inflammatory mediators.

Caladrix is committed to advancing its lead candidate, C-001, an orally available small molecule designed to activate ABCC1. This approach offers a promising alternative to monoclonal antibody therapies by avoiding ARIA risk and eliminating the need for infusion clinics, while directly restoring the brain’s natural protein homeostasis. With preclinical efficacy, translational biomarker validation, and a successful human Proof of Concept (PoC) study, Caladrix is well-positioned to make a significant impact on the treatment of neurodegenerative diseases. Caladrix has locations in Palo Alto (HQ), Melbourne (Clinical Trials) and Hamburg (R&D).

Looking ahead, Caladrix is focused on expanding its pipeline with candidates for frontotemporal dementia and other tauopathies, as well as developing modified-release formulations to ensure scalability and adherence. With a robust intellectual property portfolio and a team of highly cited researchers, Caladrix is poised to lead the next generation of non-immunologic neurodegenerative therapies. We invite the management team to create a customized and exclusive company showcase and product listing on our platform.